Weekly Evolocumab Therapy for Prevention of Recurrent Hypertriglyceridemia-Induced Pancreatitis: A Case Report
Hypertriglyceridemia-induced pancreatitis is the third most common cause of acute pancreatitis and is often severe. We describe a case of a woman in her 60s with familial hypertriglyceridemia who suffered four pancreatitis episodes within 14 months despite treatment with fibrates, niacin, omega-3 fatty acids, statins, and icosapent ethyl. Presenting triglycerides were 39.2 to 45.7 mmol/L in three episodes and 13.5 mmol/L in the fourth. She declined plasmapheresis; volanesorsen was unavailable. Off-label evolocumab 140 mg was initiated subcutaneously. Triglycerides fell 30 to 40% within 2 to 3 days of each injection (for example, from 25.4 to 17.9 mmol/L) and rose back toward baseline by day 7. She was therefore transitioned to weekly rather than the standard biweekly dosing. Over the first 12 weeks, triglycerides ranged from 13.5 to 36.0 mmol/L (median: 19.0). At 12 months, she remained pancreatitis-free without adverse effects. Weekly evolocumab may benefit selected patients with treatment-resistant hypertriglyceridemia.
Authors
- Mohamed Madani Alfagi
- Fahad Wali Ahmed (ORCID: https://orcid.org/0000-0003-4100-1571)
- Sana Javed (ORCID: https://orcid.org/0000-0002-8384-2144)
- Sagheer Ahmed
- Mubashar Sultan Kharal
Institutions
- King Faisal Specialist Hospital & Research Centre (SA)
Publication Details
- Journal
- Avicenna Journal of Medicine
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1055/s-0046-1829901
- Primary Topic
- Pancreatitis Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00